The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation

(2019) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology

(2016) Jacqueline F. Fryer et al.   BIOLOGICALS

Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples

(2016) Jutta K. Preiksaitis et al.   CLINICAL INFECTIOUS DISEASES

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

(2016) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

(2016) Margaret L Green et al.   Lancet Haematology

Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation

(2013) R. R. Razonable et al.   CLINICAL MICROBIOLOGY REVIEWS

Direct and indirect effects of cytomegalovirus: can we prevent them?

(2009) Raymund Razonable   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA